GlassScriptPhysician profile
Kenneth B Wiesner
NPI 1033287545
$673.31
in general payments reported to CMS, 2019-2025
14 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $11.18 · 2021: $131 · 2022: $12.93 · 2023: $15.63 · 2024: $21.08 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $214.40 | 2019-2024 | Tremfya |
| Abbvie INC. | $127.53 | 2025 | |
| Novartis Pharmaceuticals Corporation | $66.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.10 | 2021 | |
| Pfizer INC. | $44.93 | 2019 | |
| Glaxosmithkline, LLC. | $36.23 | 2021 | |
| Ucb, INC. | $31.64 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2019 | |
| Medexus Pharma, INC. | $15.71 | 2019 | |
| Merck Sharp & Dohme LLC | $14.61 | 2019 | |
| Amgen INC. | $12.93 | 2022 | |
| Antares Pharma, INC. | $12.74 | 2019 | |
| Horizon Therapeutics Plc | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wiesner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.